Stock comparison
IDEXX Laboratories
Galapagos N.V. Sponsored ADR
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
LKFT
Galapagos N.V. Sponsored ADR
Market cap
$1.81B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | LKFT | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 46D | IDXX |
| Benjamin Graham | 80A | 45D | IDXX |
| Philip Fisher | 75B | 53C | IDXX |
| Peter Lynch | 71B | 60C | IDXX |
| Joel Greenblatt | 83C | 42D | IDXX |
| Charlie Munger | 87A | 46D | IDXX |
| Terry Smith | 84A | 46D | IDXX |
Side-by-side metrics
| Metric | IDXX | LKFT |
|---|---|---|
| Market cap | $44.12B | $1.81B |
| P/E (TTM) | 39.0x | 3.1x |
| EV/EBIT | 31.6x | 2.9x |
| ROIC (TTM) | 40.66% | 18.22% |
| Gross margin | 62.05% | 98.01% |
| Net margin | 24.63% | 46.83% |
| Revenue CAGR 5y | 7.56% | - |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $1.81B+96%
- ROIC (TTM)40.66%vs 18.22%+55%
LKFT leads on
- Debt / Equity0.0xvs 0.7x+100%
- P/E (TTM)3.1xvs 39.0x+92%
- EV/EBIT2.9xvs 31.6x+91%
- Net margin46.83%vs 24.63%+47%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.